2021-01-26

[#DIV28SUPER] APA Division 28 Abstracts are Due Today!



Submission Portal: https://sso.apa.org/apasso/idm/apalogin?ERIGHTS_TARGET=http://apps.apa.org/convcall/proposallist.aspx

Cecilia Bergeria, Ph.D.
Instructor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
P: 410-550-1979

2021-01-21

[#DIV28SUPER] FW: NIDA Neuroscience Update January 21, 2021

Table of Contents

I.        $1000 Prize to anyone who can break this Code  http://hegp.genenetwork.org/challenge

II.      Adolescent Brain Cognitive Development SM (ABCD) Study COVID-19 supplemental data release is now available on the NIMH Data Archive(NDA) NDA website 

III.    Call for Abstracts for NIDA Genetics and Epigenetics Consortium Meeting Due Feb 1, 2021

 

I.        $1000 Prize to anyone who can break this Code  http://hegp.genenetwork.org/challenge

Richard Mott and Pjotr Prins developed a homomorphic encryption method for genotypes and phenotypes (HEGP) as described in this open access paper supported by NIDA P30DA044223, NIGMS R01 GM-123489, and Biotechnology and Biological Sciences Research Council grants BB/S017372/1, BB/R01356X/1,  HBB/P024726/1, and BB/M011585/1.  HEGP mixes up genotypes and phenotypes to make them indistinguishable from random numbers, but such that the randomization has no effect on the outcome of testing genetic association or of estimating key parameters such as heritability or the effects of individual genetic variants. It makes it possible to share encrypted datasets and perform large-scale federated mega-analyses as if the unencrypted data had been shared. Richard Mott and Pjotr Prins are offering a $1000 Prize to anyone who can break the code http://hegp.genenetwork.org/challenge.  Please forward to anyone with code breaking expertise.       

 

II.       Adolescent Brain Cognitive Development SM (ABCD) Study COVID-19 supplemental data release is now available on the NIMH Data Archive(NDA) NDA website 

The ABCD COVID-19 data release consists of survey responses from ABCD families about the impact of the pandemic on their lives. Surveys were sent electronically to all ABCD participants and their parent/guardian in May, June, August and December of 2020. Youth and parents/guardians were asked separately about school attendance and activities, sleep, daily routines, physical activity, mental health, screen time, racism/discrimination in relation to COIVD-19, COVID attitudes and practices, and coping behaviors. Importantly, researchers will be able to link data from these surveys to data from the main ABCD study visits, including those that occurred prior to the pandemic. Future releases will include data from subsequent surveys. Visit the NDA website for more information.

 

III.     Call for Abstracts for NIDA Genetics and Epigenetics Consortium Meeting Due Feb 1, 2021

The Genetics and Epigenetics Cross Cutting Research Team of the National Institute on Drug Abuse invites you to submit an abstract for the March 8-10, 2021 Virtual NIDA Genetics and Epigenetics Consortium Meeting. Oral presentations will be conducted through Webex. Submissions selected for poster presentations will have the opportunity to present their work through a SLACK Channel. Presenters using a SLACK channel must post hyperlinks to their presentations. Presentations uploaded as a file to SLACK will be removed. We encourage hyperlinks to short (e.g. 5 to 10 slides) slide decks (e.g. via Box, Google Drive or other data-sharing service) and presentations via Zoom or other similar platform. Detailed instructions will be shared in mid-February and practice sessions will be held prior to the meeting.  

 

Please submit your abstract in the following format to  NIDAGenetics@leedmci.com. By February 1, 2021:

Submitter Name:                                                                    

Submitted email:

PI Name (if different):                                                             

PI email (if different):

 

Clever title for your abstract

 

First Name Last Name1, First Name Last Name1,2, First Name Last Name3, and First Name Last Name1,4

1Department, University; 2Department, University; 3Department, University; 4Department, University

 

The Abstract should discuss the background, rationale/significance, hypothesis, results and discussion. The font size should be Arial 11 pt. The body of the abstract should be 250 words, maximum and fully justified. Please submit the abstract as a word document. Abstracts are due by Midnight PST on February 1, 2021. Abstracts not conforming to this format or sent to another email will not be accepted for review and may be returned to the sender. Abstracts sent to another email will not be returned.

 

See examples at:  (2020 NIDA Genetics Consortium Meeting Abstracts). 

The goals of the meeting are to:

  • Showcase the exciting research on the genetics and epigenetics of substance use disorders
  • Encourage collaboration among investigators with different expertise in genetics and epigenetics
  • Foster collaboration between investigators working on the genetics and epigenetics of substance abuse disorders and HIV/AIDS investigators
  • Identify new research opportunities in the genetics and epigenetics of substance use disorders 
  • Provide attendees with an opportunity to meet with NIDA program directors to discuss their ideas for grant applications and funding opportunities   

The NIDA Genetics and Epigenetics Cross-Cutting Research Team will select up to 30 abstracts for short talks. We may invite some investigators to serve as panel discussants. Abstracts not selected for talks may be assigned poster presentations. Abstracts should focus on the genetics and epigenetics of substance abuse in humans or in model systems. We encourage submissions across all career stages (e.g. graduate students, postdoctoral scientists, junior and senior faculty). Abstracts are due by Midnight PST on Monday, February 1, 2021. Decisions on acceptance of poster presentations and short talks will be made on a rolling basis.   

 

----------------------

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L

 

 

 

[#DIV28SUPER] T32 Postdoctoral Fellowship at the University of Florida

Dear Colleagues,

Under the auspices of our T32 program (below), I am recruiting a postdoctoral fellow to contribute to our research on the etiology of alcohol misuse and sexual health behaviors and development and testing of new interventions (primarily e/m-health, primarily among adolescents/young adults) to reduce alcohol use and prevent HIV.  The University of Florida is an outstanding research and training environment in general, and particularly in addictive behaviors and HIV/sexual health research. Please share with other colleagues and any interested potential candidates.

My esteemed colleagues below would also be open to recruiting a postdoc to contribute to an array of projects in data science; cognition; epidemiology; biomarkers/sensor technology; relationships among effects of aging, alcohol use and/or HIV; the natural history/process of recovery; and many other areas.

While all postdocs will conduct research on alcohol and HIV during their fellowship, successful applicants need not have a substantial prior background in both areas.

Best,

Rob Leeman




Robert F. Leeman, Ph.D.
Associate Professor

Mary F. Lane Endowed Professor

Department of Health Education and Behavior

College of Health and Human Performance

Co-Director, NIH/NIAAA T32: Translational Science Training to Reduce the Impact of Alcohol on HIV Infection

Associate Director, Southern HIV & Alcohol Research Consortium (SHARC)

University of Florida

Florida Gymnasium, Room 14

PO Box 118210     Gainesville, FL  32611

Phone: (352) 294-1808

Email: robert.leeman@ufl.edu

Faculty webpage: Robert Leeman, Ph.D. - College of Health and Human Performance (ufl.edu)

Lab webpage: EDGE Lab - College of Health and Human Performance (ufl.edu)

Twitter: @LeemanRobertF




  

POSTDOCTORAL FELLOWSHIP

IN HIV AND ALCOHOL RESEARCH

Southern HIV and Alcohol Research Consortium (SHARC)

University of Florida

 

The Southern HIV and Alcohol Research Consortium (SHARC) at the University of Florida seeks Postdoctoral Fellows interested in translational science research and training focused on reducing the impact of alcohol on HIV infection, behavioral and clinical interventions, and/or neurocognition and brain science.

 

Fellows are supported by a T32 training grant funded by the NIH National Institute on Alcohol Abuse and Alcoholism.

 

Postdoctoral Fellows will develop an original research program under the guidance of a faculty mentor, participate in research seminars and training experiences, and engage in individual and group mentoring sessions with distinguished faculty mentors including Co-Directors Drs. Robert Cook, Robert Leeman, and Robert Lucero together with faculty colleagues representing diverse disciplines across the university.

 

SHARC faculty mentors are affiliated with six departments and four colleges at the University of Florida, including:

 

 

Clinical & Health Psychology: Jeff Biossoneault, PhD; Ronald Cohen, PhD;

              Eric Porges, PhD; Catherine Price, PhD, ABPP; Adam Woods, PhD

 

Epidemiology: Robert L. Cook, MD, MPH; Xinguang Chen, MD, PhD, FACE;

              Linda Cottler, PhD, MPH, FACE; Mattia Prosperi, MEng, PhD; Yan Wang, PhD

 

Health Education & Behavior: Robert Leeman, PhD; JeeWon Cheong, PhD; Jalie Tucker, PhD, MPH

 

      Nursing: Robert Lucero, PhD, MPH, RN, FAAN; Anna McDaniel, PhD, RN, FAAN; Diana Wilkie, PhD, RN, FAAN

 

Pathology: Marco Salemi, PhD

 

Psychiatry & Psychology: Sara Jo Nixon, PhD

 

 

For more information about the SHARC T32 training program and to learn about application requirements, we invite you to visit our program website at

https://sharc-research.org/get-involved/t32-training/ or email sharct32@phhp.ufl.edu or any of the faculty mentors listed above.

 

Preliminary inquiries should include the following documents and may be submitted by email to sharct32@phhp.ufl.edu:

·         Statement of Interest

·         Curriculum Vitae

 

Applying:

All appointments to this training grant are restricted to U.S. citizens, legal permanent residents of the U.S. and noncitizen nationals. Persons on temporary or student visas or who require visa sponsorship are not eligible for this training grant.

 

Start Date: 

Review of applications will be conducted on a rolling basis. Initial appointment will be for 12 months and is renewable annually up to two years contingent upon satisfactory performance and availability of funding.

 

Compensation:

Trainees receive stipends at standard NIH levels (NIH levels are described here: (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-070.html) as well as financial support for research and travel expenses and health insurance.

 

Diversity and Inclusion:

The University of Florida is an equal opportunity institution. Individuals from underrepresented populations are strongly encouraged to apply for this postdoctoral opportunity. We highly encourage the applications of scholars from diverse backgrounds and experiences, scholars of color, scholars from rural backgrounds, scholars who have been the first in their families to pursue postsecondary or postgraduate education, and scholars interested in using academic research to drive social change.

 

 

 

[#DIV28SUPER] Post-Doctoral Fellowships Available at the University of Kentucky

Sending on behalf of Dr. Craig Rush:

Dear Colleagues,

I am writing to let you know we will be accepting applications for post-doctoral fellows on our NIDA-supported training grant in the Department of Behavioral Science at the University of Kentucky (T32 DA035200; "Research Training in Drug Abuse Behavior"). Applications are due at noon Eastern on April 15, 2021; only US citizens or permanent residents are eligible. Please contact me at crush2@email.uky.edu for more details or a list of training faculty.

Thank you,

Craig Rush, Director, T32DA035200

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2021-01-19

[#DIV28SUPER] FW: Final Recommendation Statement: Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons

Dear Colleagues,

 

The U.S. Preventive Services Task Force (USPSTF) just released final recommendations and an evidence summary on interventions for tobacco cessation in adults, including pregnant persons. A clinician summary is also available on the Task Force website, which provides guidance to primary care clinicians for using the recommendation in practice.

 

To view the recommendation and evidence summary, please click here:  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions

 

Please forward to interested colleagues.

 

Thank you.

 

Jacob S. Marzalik, MA

Project Manager, Clinical Practice Guidelines

Practice Transformation and Quality, Practice Directorate

American Psychological Association

 

750 First Street NE, Washington, DC 20002-4242

202-336-5872

 

All APA staff are teleworking until further notice and are experiencing a high volume of inquiries related to COVID-19. For immediate information and resources, visit APA's COVID-19 page for psychologists, health-care workers, and the public.

 

From: Agency for Healthcare Research and Quality (AHRQ) <updates@subscriptions.ahrq.gov>
Sent: Tuesday, January 19, 2021 11:50 AM
To: Marzalik, Jacob <JMarzalik@apa.org>
Subject: Final Recommendation Statement: Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons

 

 

u s preventive services task force

January 19, 2021

Final Recommendation Statement:

Interventions for Tobacco Cessation in Adults

Final Recommendation Statement: Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons

The U.S. Preventive Services Task Force released today a final recommendation statement on interventions for tobacco smoking cessation in adults, including pregnant persons. The Task Force recommends clinicians ask about tobacco use and connect people to proven, safe methods to help them quit. The evidence is unclear whether e-cigarettes help adults quit smoking. More research is needed on the benefits and harms of using medications to help pregnant people quit. To view the recommendation, the evidence on which it is based, and a summary for clinicians, please go here. The final recommendation statement can also be found in the January 19, 2021 online issue of JAMA.

The Final Recommendation Statement Is Available

read the final recommendation

FINAL RECOMMENDATION SUMMARY

See the full statement

Population

Recommendation

Grade

Nonpregnant adults

The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and US Food and Drug Administration (FDA)--approved pharmacotherapy for cessation to nonpregnant adults who use tobacco.

A

Pregnant persons

The USPSTF recommends that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.

A

Pregnant persons

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant persons.

I

All adults

he USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of electronic cigarettes (e-cigarettes) for tobacco cessation in adults, including pregnant persons. The USPSTF recommends that clinicians direct patients who use tobacco to other tobacco cessation interventions with proven effectiveness and established safety.

I

WHY THIS MATTERS

Michael Silverstein"Quitting is the most important step a smoker can take to lead a longer and healthier life,” says Task Force member Michael Silverstein, M.D., M.P.H. “The good news is there are multiple safe and proven ways to help adults quit tobacco, including counseling, medications, or a combination of both.”

WHERE WE ARE IN THE PROCESS

Draft

Research Plan

Final

Research Plan

Draft

Recommendation / Draft Evidence Review 

Final Recommendation / Evidence Summary


This email was sent to jmarzalik@apa.org using GovDelivery Communications Cloud on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 5600 Fishers Lane, Rockville, MD 20857 · 301-427-1364 


CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

2021-01-14

[#DIV28SUPER] APA Division 28 wants to highlight YOUR psychopharmacology and substance use research - Abstracts now due Jan 26


Convention Link:

Submission Portal:



Cecilia Bergeria, Ph.D.
Instructor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
P: 410-550-1979

2021-01-13

[#DIV28SUPER] Coordinator II Position Available at the University of Florida

Dear Colleagues,

 

I am hiring a Research Coordinator II in my research group in the Department of Health Education & Behavior at the University of Florida to contribute to our studies on etiology of addictive behaviors and development/testing of new interventions to ameliorate these behaviors, particularly technology-based interventions, primarily (though not exclusively) in the young adult population. This RC II will be in an overseeing and supervisory role so I am looking for someone with prior experience. This person will also contribute to academic tasks like literature searches, potentially preliminary data analysis and collaboration on conference presentations and manuscripts in which we use great words like ameliorate. The link is below. Please spread widely and don’t hesitate to reach out with any questions. As of now, we are a group with three professional/paid research assistants, three doctoral students, an MPH intern and about a dozen undergraduates. I am biased but I feel that we have a good culture where we get along well and work collaboratively.

 

Best,

 

Rob Leeman

 

 

https://explore.jobs.ufl.edu/en-us/job/515453/research-coordinator-ii

 

 

Robert F. Leeman, Ph.D.
Associate Professor

Mary F. Lane Endowed Professor

Department of Health Education and Behavior

College of Health and Human Performance

Co-Director, NIH/NIAAA T32: Translational Science Training to Reduce the Impact of Alcohol on HIV Infection

Associate Director, Southern HIV & Alcohol Research Consortium (SHARC)

University of Florida

Florida Gymnasium, Room 14

PO Box 118210     Gainesville, FL  32611

Phone: (352) 294-1808

Email: robert.leeman@ufl.edu

Faculty webpage: http://hhp.ufl.edu/about/faculty-staff/leeman_robert/

Lab webpage: http://hhp.ufl.edu/faculty-research/labs/edge-lab/

Twitter: @LeemanRobertF

 

 

2021-01-11

[#DIV28SUPER] EXTENDED DEADLINE: APA Division 28 (Psychopharmacology and Substance Abuse) Call for Proposals

Greetings Division 28 members and affiliates,

APA has extended the deadline for abstract submissions by 2 weeks. Proposals are now due by January 26th, 5:00 EST.  Please use this extra time to develop your abstract to present as part of Division 28's programming.

As a reminder, all Divisional programming for this year's meeting will be virtual. This means you will have an easy opportunity to help promote your science and expand your CV without the need for travel. This is a great way to interact with your colleagues and contribute to our mission of promoting rigorous and clinically-impactful science in the area of psychopharmacology and substance use. We are excited to follow up on the tremendous job of our 2020 program chair Justin Strickland to put together an innovative and fun convention program for you but we rely on your submissions to make that happen.

Please email our 2021 Program Chair Dr. Cecilia Bergeria (cberge21@jhmi.edu) or myself as Division 28 President (kdunn9@jhmi.edu) if you need assistance developing or submitting your proposal.


Warm regards,

Kelly Dunn
President, Division 28

---
Kelly Dunn, Ph.D., M.B.A.
Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030


From: div28super reaches div28 and div28m and its nested lists (e.g. div28s) <DIV28SUPER@LISTS.APA.ORG> on behalf of Cecilia Bergeria <cberge21@JHMI.EDU>
Sent: Monday, January 4, 2021 3:35 PM
To: DIV28SUPER@LISTS.APA.ORG <DIV28SUPER@LISTS.APA.ORG>
Subject: [#DIV28SUPER] APA Division 28 (Psychopharmacology and Substance Abuse) Call for Proposals
 


Cecilia Bergeria, Ph.D.
Instructor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
P: 410-550-1979

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28